Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma

NCT00953446 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT00953446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00953446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Not applicable
Overall status
Terminated
Start date
June 15, 2010
Completion date
September 13, 2011
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma